Date Title Description PDF
22 Feb 2022 On buy-back programmes ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022.     Download
16 Feb 2022 On business and financial situation Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years       Download
03 Nov 2021 On buy-back programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Download
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download
22 Jun 2021 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Download

Pages

Date Title Description PDF
31 Jul 2024 Liquidity and counterparty agreements Modification of securities and cash balances associated with the Liquidity Contract signed between the Company and Bestinver, S.V., S.A. Download
08 Jul 2024 Other relevant information The Company informs about the dividends payment.   Download
04 Jul 2024 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the second quarter of 2024 Download
24 Jun 2024 Announcement of General Shareholders' Meeting The Company reports on the resolutions adopted by the Ordinary General Shareholders' Meeting and by the Board of Directors. Download
11 Jun 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 7 June 2024 and 11 June 2024 and end of the share buyback program Download

Pages

Date Title Description PDF
05 Oct 2017 Contratos de liquidez y contrapartida Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. Download
03 Oct 2017 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted from 11 July to 30 September 2017   Download
07 Sep 2017 Otros sobre negocio y situación financiera The Company informs that commences the enoxaparin biosimilar marketing in Germany Download
26 Jul 2017 Información sobre resultados ROVI releases the presentation related to the 2017 first half results Download
26 Jul 2017 Información sobre resultados ROVI releases the presentation related to the 2017 first half results Download

Pages